Research News
Improving Cancer Care: The Importance of Hepatitis B Screening Before Chemotherapy
A systematic review and meta-analysis reveal that hepatitis B virus (HBV) screening rates in cancer patients before chemotherapy remain suboptimal globally. Conducted by researchers from Chulalongkorn University and affiliated institutions, the study analyzed data from 29 studies across various regions, reporting an overall screening rate of 57%.
Key findings include significant variations in screening rates based on geographic endemicity, cancer type, and chemotherapy regimens. Patients receiving rituximab-containing chemotherapy and those with hematological malignancies had higher screening rates. Despite improvements over time, disparities persist, highlighting the need for adherence to clinical guidelines and tailored strategies to enhance HBV screening practices in cancer care.
The research underscores the importance of early HBV identification and prophylactic measures to prevent potentially life-threatening reactivation during immunosuppressive therapy.
Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hos-
pital, Thai Red Cross Society, 1873 Rama IV Road, Patumwan, Bangkok, 10330, Thai-
land.